The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....

Unprecedented industry collaboration topped the “Best of 2020” list for BioCentury’s editorial team for a year in which there was no question what topped the “Worst” list. On the latest edition of...

On the latest edition of the BioCentury this Week podcast, BioCentury editors discuss the latest advances and setbacks among COVID-19 vaccines in the wake of FDA’s emergency use authorization on Friday for Pfizer and BioNTech’s...

Bispecific antibodies are top of mind at this year’s ASH meeting as they start to venture into new targets and indications in the clinic. On the latest edition of the BioCentury This Week podcast,...

After its latest readout positioned the company to seek FDA authorization of its COVID-19 vaccine, Moderna has begun to look ahead to unblinding the Phase III trial of mRNA-1273 so participants who received a placebo can be...

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to...

A modestly-priced acquisition of an NK cell platform company in spring 2019 set up Kiadis for a premium takeout by its partner Sanofi, even after the Dutch biotech discontinued its lead T cell program late...

Once much maligned, special purpose acquisition companies have become a viable path to the public markets for top-tier biotechs this year. On the latest BioCentury This Week podcast, BioCentury editors...

A UCSF-led team has identified host pathways that could inform development of countermeasures against future coronaviruses, as they interact with multiple coronaviruses that recently made the leap...